Can a bone drug help women with anorexia? small study hints at hope

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion/Exclusion Criteria: Inclusion Criteria: * Female * Age 20-60 years, skeletally mature with closed epiphyses * Anorexia nervosa or atypical anorexia nervosa defined by DSM-V diagnostic criteria * BMD T-score \< -1.0 * Normal serum 25-OH vitamin D (\>30 ng/mL) and calcium levels * For women of reproductive age, agree to use an effective contraceptive method. Highly effective methods of birth control include: * Combined (estrogen and progestogen) hormonal methods (pills, vaginal ring, or skin patch) * Intrauterine device (IUD) * Intraduterine hormonal-releasing system (IUS) * Surgery to tie both fallopian tubes (bilateral tubal ligation/occlusion) * Your male partner has had a vasectomy and testing shows there is no sperm in the semen * Dental check up within the past year Exclusion Criteria: * Any disease known to affect bone, including untreated thyroid dysfunction, Cushing's or renal failure * Subjects with a known esophageal disease cannot participate in the alendronate extension study * Any medication known to affect bone metabolism within 3 months of the study, excluding oral contraceptives or other forms of estrogen administration. Bisphosphonates must have been discontinued for at least one year before participation * Immunodeficiency or taking immunosuppressive therapy * Serum potassium \<3.0 meq/L * Serum ALT \>3 times upper limit of normal * eGFR of less than 30 ml/min * Hypocalcemia * Diabetes mellitus * Active substance abuse, including alcohol * History of malignancy * Paget disease of bone * Osteomalacia * Osteonecrosis of the jaw (ONJ) or risk factor for ONJ, such as invasive dental procedures (eg, tooth extraction, dental implants, oral surgery in the past 6 months), poor oral hygiene, periodontal and/or pre-existing dental disease, and current use of corticosteroids. * Planned invasive dental procedure over the next 24 months. * Known senstivity to any of the products or components to be administered during dosing or known sensitivity to mammalian cell derived drug products * Sensitivity to calcium or vitamin D supplements * Pregnant, planning to become pregnant with 7 months after the end of treatment and/or breastfeeding